

# Katherine K Matthay

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2464510/katherine-k-matthay-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

131  
papers

14,440  
citations

56  
h-index

120  
g-index

134  
ext. papers

17,078  
ext. citations

7.1  
avg, IF

5.81  
L-index

#	Paper	IF	Citations
131	Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. <i>New England Journal of Medicine</i> , <b>1999</b> , 341, 1165-73	59.2	1502
130	Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 1324-34	59.2	1144
129	The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 289-97	2.2	1134
128	The International Neuroblastoma Pathology Classification (the Shimada system). <i>Cancer</i> , <b>1999</b> , 86, 364-372	37.2	781
127	Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1007-13	2.2	648
126	The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 298-303	2.2	613
125	Neuroblastoma. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16078	51.1	524
124	Advances in Risk Classification and Treatment Strategies for Neuroblastoma. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3008-17	2.2	433
123	Chromosome 1p and 11q deletions and outcome in neuroblastoma. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 2243-53	59.2	415
122	Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. <i>Journal of Pediatric Hematology/Oncology</i> , <b>1999</b> , 21, 181-9	1.2	274
121	International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. <i>Cancer</i> , <b>2001</b> , 92, 2451-61	6.4	220
120	Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 999-1008	21.7	205
119	Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 477-86	2.2	195
118	Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1054-60	2.2	194
117	Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 1313-23	59.2	190
116	Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. <i>Cancer</i> , <b>2003</b> , 98, 2274-81	6.4	189
115	Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3286-92	2.2	187

114	Drugging MYCN through an allosteric transition in Aurora kinase A. <i>Cancer Cell</i> , <b>2014</b> , 26, 414-427	24.3	179
113	Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3525-32	2.2	175
112	Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. <i>Medical and Pediatric Oncology</i> , <b>2001</b> , 36, 612-22		157
111	Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment. <i>Cancer</i> , <b>1988</b> , 62, 818-25	6.4	153
110	Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 500-6	2.2	148
109	Promising therapeutic targets in neuroblastoma. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2740-53	12.9	144
108	Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2580-2587	2.2	142
107	Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. <i>Journal of Nuclear Medicine</i> , <b>2013</b> , 54, 541-8	8.9	135
106	Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group. <i>Pediatrics</i> , <b>2007</b> , 120, e1229-36	7.4	133
105	Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1842-8	2.2	128
104	Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. <i>Journal of the National Cancer Institute</i> , <b>1995</b> , 87, 1470-6	9.7	128
103	Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2003</b> , 56, 28-39	4	125
102	Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 85-91	2.2	120
101	Neuroblastoma in adults and adolescents: an indolent course with poor survival. <i>Cancer</i> , <b>1997</b> , 79, 2028-35	3.4	118
100	Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2142-9	2.2	116
99	Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. <i>Cancer</i> , <b>2001</b> , 92, 2699-708	6.4	110
98	Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3169-76	2.2	106
97	Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. <i>The American Journal of Pediatric Hematology/oncology</i> , <b>2000</b> , 22, 315-20		105

96	Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4351-7	2.2	104
95	Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6474-80	2.2	104
94	Neuroblastoma: clinical and biological approach to risk stratification and treatment. <i>Cell and Tissue Research</i> , <b>2018</b> , 372, 195-209	4.2	96
93	Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1020-5	2.2	94
92	Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 365-70	2.2	92
91	Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. <i>Cancer Letters</i> , <b>2005</b> , 228, 275-82	9.9	92
90	Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 2452-60	2.2	92
89	Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. <i>Journal of Pediatric Surgery</i> , <b>2004</b> , 39, 931-6	2.6	88
88	Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. <i>Cancer</i> , <b>2003</b> , 98, 155-65	6.4	86
87	Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1368-75	2.2	83
86	Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3808-15	2.2	83
85	Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. <i>Medical and Pediatric Oncology</i> , <b>2001</b> , 36, 623-9		83
84	Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 561-71	7.5	81
83	SUN-345 Safety Analysis of High-Specific-Activity I-131 MIBG (AZEDRA <sup>®</sup> ) in Patients with Iobenguane Scan Positive Cancers. <i>Journal of the Endocrine Society</i> , <b>2019</b> , 3,	0.4	78
82	Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. <i>Cancer</i> , <b>2017</b> , 123, 4224-4235	6.4	73
81	Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. <i>Pediatric Blood and Cancer</i> , <b>2006</b> , 47, 865-74	3	71
80	Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2003</b> , 25, 543-7	1.2	68
79	Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 115ra3	17.5	66

78	131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 673-81	4.7	64
77	Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 68, 1057-65	3.5	64
76	Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. <i>Pediatric Blood and Cancer</i> , <b>2013</b> , 60, 1801-8	3	62
75	Phase I study of vincristine, irinotecan, and <sup>131</sup> I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2679-86	12.9	56
74	Patient-specific dosimetry using pretherapy <sup>123</sup> I-m-iodobenzylguanidine ( <sup>123</sup> I-MIBG) dynamic PET/CT imaging before <sup>131</sup> I-MIBG targeted radionuclide therapy for neuroblastoma. <i>Molecular Imaging and Biology</i> , <b>2015</b> , 17, 284-94	3.8	54
73	Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. <i>Cancer Letters</i> , <b>2011</b> , 306, 223-9	9.9	54
72	Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 1155-63	8.9	54
71	Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 2339-49	12.9	50
70	Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2715-21	12.9	47
69	A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. <i>Pediatric Blood and Cancer</i> , <b>2016</b> , 63, 1349-56	3	46
68	SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings. <i>Pediatric Blood and Cancer</i> , <b>2015</b> , 62, 1305-16	3	45
67	Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4358-64	2.2	45
66	Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. <i>Cancer</i> , <b>2016</b> , 122, 935-45	6.4	44
65	Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma. <i>Pediatric Blood and Cancer</i> , <b>2011</b> , 56, 191-201	3	41
64	Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , <b>2009</b> , 52, 44-50	3	41
63	131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. <i>Pediatric Blood and Cancer</i> , <b>2013</b> , 60, 879-84	3	40
62	Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131I)-metaiodobenzylguanidine ((131I)-MIBG). <i>European Journal of Cancer</i> , <b>2015</b> , 51, 2465-72	7.5	39
61	Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 6142-6149	12.9	39

60	Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. <i>European Journal of Cancer</i> , <b>2016</b> , 65, 1-10	7.5	39
59	Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular. <i>Cancer</i> , <b>2000</b> , 89, 1150-1164	11.4	37
58	Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 189-196	12.9	36
57	Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. <i>International Journal of Molecular Imaging</i> , <b>2012</b> , 2012, 250834		36
56	Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 292-305	8.8	33
55	Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 502-508	8.9	32
54	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2179-2189	12.9	30
53	Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 115-124	12.2	26
52	Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5374-5383	12.9	25
51	MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , <b>2017</b> , 64, e26545	3	25
50	Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. <i>Pediatric Blood and Cancer</i> , <b>2014</b> , 61, 1932-9	3	25
49	Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3243-3255	2.2	24
48	Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma. <i>Medical and Pediatric Oncology</i> , <b>1998</b> , 30, 339-46		24
47	Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 89, 839-45	4	23
46	Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. <i>Pediatric Blood and Cancer</i> , <b>2018</b> , 65, e27023	3	22
45	Current treatment and outcome for childhood acute leukemia in Tanzania. <i>Pediatric Blood and Cancer</i> , <b>2013</b> , 60, 2047-53	3	22
44	Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 97, 270-277	4	20
43	The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma. <i>Pediatric Blood and Cancer</i> , <b>2012</b> , 58, 675-81	3	20



42	Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. <i>The Lancet Child and Adolescent Health</i> , <b>2018</b> , 2, 25-34	14.5	19
41	Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. <i>European Journal of Cancer</i> , <b>2016</b> , 66, 144-52	7.5	18
40	Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3643-50	12.9	18
39	Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG). <i>Pediatric Blood and Cancer</i> , <b>2016</b> , 63, 436-42 <sup>3</sup>		16
38	Prenatal diagnosis of chronic granulomatous disease. <i>American Journal of Medical Genetics Part A</i> , <b>1984</b> , 17, 731-9		15
37	Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. <i>Pediatric Blood and Cancer</i> , <b>2019</b> , 66, e27819	3	14
36	Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 474-481	8.8	13
35	I-MIBG PET/CT to Monitor Metastatic Disease in Children with Relapsed Neuroblastoma. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 43-47	8.9	12
34	Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. <i>Oncotarget</i> , <b>2017</b> , 8, 23851-23861	3.3	10
33	Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 311-3	12.9	9
32	Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2031-2039	4.7	8
31	Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for I-MIBG therapy of neuroblastoma using I-MIBG PET/CT. <i>Medical Physics</i> , <b>2019</b> , 46, 2477-2486	4.4	8
30	Interleukin 2 plus anti-GD2 immunotherapy: helpful or harmful?. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1549-1557	5.1	8
29	Comparison of Clinical Features and Outcomes in Patients With Bilateral Versus Unilateral Adrenal Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2017</b> , 39, 108-113	1.2	7
28	Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. <i>Clinical Sarcoma Research</i> , <b>2016</b> , 6, 9	2.5	7
27	Extended Sedation With Continuous Midazolam or Dexmedetomidine Infusion for Young Children Receiving 131 I-MIBG Radiopharmaceutical Therapy for Advanced Neuroblastoma. <i>Pediatric Blood and Cancer</i> , <b>2016</b> , 63, 471-8	3	7
26	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3506-3514	2.2	7
25	Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. <i>Pediatric Blood and Cancer</i> , <b>2019</b> , 66, e27736	3	6

24	Estimation of intra-arterial chemotherapy distribution to the retina in pediatric retinoblastoma patients using quantitative digital subtraction angiography. <i>Interventional Neuroradiology</i> , <b>2018</b> , 24, 214-219	1.9	6
23	Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , <b>2018</b> , 65, e26940	3	5
22	Physician Perspectives on Palliative Care for Children With Neuroblastoma: An International Context. <i>Pediatric Blood and Cancer</i> , <b>2016</b> , 63, 872-9	3	4
21	Impact of Post-Induction Curie Scores in High-Risk Neuroblastoma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, S107	4.7	4
20	A large prospective trial of children with unilateral retinoblastoma with and without histopathologic high-risk features and the role of adjuvant chemotherapy: A Children's Oncology Group (COG) study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 9515-9515	2.2	4
19	Association of image-defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma. <i>Cancer Medicine</i> , <b>2021</b> , 10, 2232-2241	4.8	4
18	Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After I-Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 99, 468-475	4	3
17	A safety and feasibility trial of I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , <b>2021</b> , 68, e29117	3	3
16	International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors <b>2001</b> , 92, 2451		3
15	Advancing therapy for neuroblastoma. <i>Nature Reviews Clinical Oncology</i> ,	19.4	3
14	Congenital malformation syndromes associated with peripheral neuroblastic tumors: A systematic review. <i>Pediatric Blood and Cancer</i> , <b>2019</b> , 66, e27901	3	2
13	Is liver metastasis in neuroblastoma an indication for treatment reduction?. <i>Pediatric Blood and Cancer</i> , <b>2006</b> , 46, 269-70	3	2
12	The International Neuroblastoma Pathology Classification (the Shimada system) <b>1999</b> , 86, 364		2
11	Global Neuroblastoma Network: An international multidisciplinary neuroblastoma tumor board for resource-limited countries.. <i>Pediatric Blood and Cancer</i> , <b>2022</b> , e29568	3	1
10	High-Risk Neuroblastoma and Current Protocols <b>2020</b> , 213-235		1
9	Germline MUTYH Mutation in a Pediatric Cancer Survivor Developing a Secondary Malignancy. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2020</b> , 42, e647-e654	1.2	1
8	Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors <b>2001</b> , 92, 2699		1
7	Evaluation and Outcome of Central Nervous System Involvement in Pediatric Acute Lymphoblastic Leukemia in Dar es Salaam, Tanzania. <i>Pediatric Blood and Cancer</i> , <b>2016</b> , 63, 458-64	3	0



6	Anatomic patterns of relapse and progression following treatment with I-MIBG in relapsed or refractory neuroblastoma. <i>Pediatric Blood and Cancer</i> , <b>2021</b> , e29396	3	0
5	Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.. <i>Pediatric Blood and Cancer</i> , <b>2022</b> , e29616	3	0
4	Reply: Is Extended Sedation Necessary for Young Children Receiving High-Dose (131) I-MIBG Therapy?. <i>Pediatric Blood and Cancer</i> , <b>2016</b> , 63, 1868	3	
3	Outcome analysis of non-high-risk neuroblastoma patients enrolled on Children's Oncology Group trials P9641 and A3961.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 9533-9533	2.2	
2	Comparison of Taqman low density array (TLDA) five-gene assay for tumor cells in bone marrow and blood with histologic bone marrow examination and imaging for disease assessment and outcome in patients with recurrent/refractory neuroblastoma (NBL): A new approaches to neuroblastoma therapy (NANT) study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 10039-10039	2.2	
1	Langerhans' Cell Histiocytosis325-330		